Member Info for Diversified

But this is an excellent critical care article that tells you exactly why I.v. Interferon beta is considered to have an important role to play in fighting COVID, with the solidarity trial and Remap Cap trials to soon shed light on its effectiveness.

https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03048-5

Another tick in the box for IFN-B.

‘Importantly, dACE2 cannot bind to the SARS-CoV-2 spike protein receptor-binding domain and lacks carboxypeptidase activity, dispelling concerns that IFN treatment might enhance viral infection.’

We have a high probability that Remdisivir and IFN-B is a combination therapy within the solidarity trial too. IFN-B is gaining traction globally that’s for sure.

I expect interim results to be negative for the combination/HIV drugs but significant enough to consider traumakine as a sole treatment which will give Farn the publication it deserves. It’s worth translating that whole article.

As for results for this new sole treatment, end of September in my book. Interim update would appear to be imminent.

So now we know why IFN-B is being trialed one it’s own. It would appear this ‘promising’ treatment is being accessed as a sole treatment as per comms from Columbia, Nigeria, Kenya etc. This in itself as I have said before is extremely encouraging.

Pyritz: A few days ago, the British biotech company Synergen reported promising results in the treatment of corona patients with the drug beta interferon for inhalation. Do the results of the Solidarity Study point in a similar direction?

Welte: The problem with Solidarity, the large WHO study, is that beta interferon was never given as a single therapy, but always in combination with other drugs. And with that it is very difficult to say anything about the effectiveness of the mono substance. The data published by the company on the Internet are also very cursive, one would have to look much more deeply, especially when it came to the question of whether the patient groups were comparable and how much concomitant medication the patients had to be able to give a final assessment . But at least it is an approach that at least for the time being seems promising.

Released: 5 hours ago

https://www.deutschlandfunk.de/who-studie-zu-wirkstoffen-gegen-corona-remdesivir-ist-nicht.676.de.html?dram:article_id=481517

T - trust me, if this trial is successful the world will know about Farn and the big boys will be all over this. With the current free float you can only imagine the reaction in the share price. I’ll leave it their as nothing is guaranteed, but the Solidarity trial will be desperate for success.

The earlier clip also only mentions IFN-B as the second treatment so I am convinced that they have seen enough to persevere with IFN-B to continue the trials since the other drugs were dropped in early July.

Based on a 28 day trial we should be approaching decent numbers as only one of two treatments in the current trial globally.

Thank you for the links. Market maker games are playing into long term holder hands here and general market sentiment hasn’t helped following U.S GDP numbers.

I want to leave some dry gunpowder available to average down in the event of negative trials as that in itself would provide an opportunity with Clevergen being the main play here in the medium term, however the lower this goes the more greedy I become which is a challenge in itself.

I find it interesting that they intend to add new treatments to the trial in the near future which should at least give us an update on where the current treatments are. With a second wave now becoming more likely in Europe I think the urgency may have increased somewhat!

She mentions around 9:40 ARDS but I can’t understand her as the interview is not very clear, but I’m sure we are referred to as an encouraging new drug.

https://youtu.be/-J1F8h9gm_4

It would appear from recent communication from those joining the trial that IFN-B is being administered as a stand alone treatment and no longer in conjunction with lopinavir/ritonavir as these two additional treatments are no longer being mentioned.

That to me would suggest that the IFN-B is responsible for improvements in candidates in its own right.

If this is the case I think we can take great Encouragement by the fact that the trial has evolved to this point and we are still part of the race.

What do we think the share price would be if the WHO referred to IFN-B as Traumakine? FARN is so under the radar with mainstream publicity it is untrue!

I have seen many references to the CEO saying that he expects to see significant gains in the next 9/12 months. Can anyone assist in providing a link to the interview or statement where he made this statement please? I can’t find it!

Brilliant video, and a further interview with the same guy here who makes direct reference to just two treatments, ‘very promising treatments’, and we all know this is Traumakine.

https://twitter.com/newzroom405/status/1288357517328883712?s=21

This is becoming a bit to obvious to be true. It’s like having a winning lottery ticket for a future draw and all I have to do is be patient. Surely it can’t be that easy!

Clevergen is the monster that has enabled higher than normal exposure to Traumakine as it can minimize downside exposure over the medium term.

This articles imply’s results from the solidarity trials in a few weeks, bottom line is know one really knows at this stage other than the fact they are overdue:

https://www.newscientist.com/article/2250176-which-covid-19-treatments-work-and-how-close-are-we-to-getting-more/

We know that the interim results from the WHO solidarity trial are now over a week overdue:

https://www.reuters.com/article/us-health-coronavirus-who/who-sees-first-results-from-covid-drug-trials-within-two-weeks-idUSKBN244219

And that the probability is that those results are being peer reviewed to a point that they can release any positive findings with absolute confidence.

We also know that Columbia, South Africa and Nigeria amongst others have recently started the solidarity trial with a big emphasis on Remdisivir and IFN-B.

I am left thinking that with the WHO are now fully aware of the initial results. Yet they are now sending out further treatments to these newly initiated trials. Surely they wouldn’t of sent the treatment if they knew that the initial results were poor!?

It’s hard not to get carried away and buy the dips on this stock, I’m desperately trying not to go from overweight to drowning in FARN shares.

As of this month the solidarity trial continues to be extended to additional countries such as Nigeria and Columbia with the two main buzz words being Remdisivir and IFN-B. This wouldn’t be the case unless they were seeing positive results imo.

We know that the WHO trial is about finding a number of treatments in the fight against COVID, the more treatments we have the better the chance of survival. It’s not 1 v the other, it’s what combination or sole treatment gets you on the road to recovery.

What is becoming a common theme is that whether as a combination treatment or a treatment in isolation, IFN-B is gaining recognition and in turn credibility.

We know from that WHO website that the preliminary results are being peer-reviewed and therefore I am confident that an initial readout is imminent.

However, Nigeria and Columbia have just begun trails and expect these to run until year end so ongoing data should continue to support any guidance.

Fact remains this is still a high risk investment, we have many catalysts in the short to medium term:

- Traumakine production update
- WHO solidarity trial
- REMAP
- HIBISCUS funding and initiation
- Clevegen which could be huge in its own right
- Partner discussions

To consider a market cap of just over £200m, with as many rolls of the dice to come as FARN has, I take confidence in the fact that it’s not a one trick pony, and that COVID is a side track to its core business objectives.

Taking all this into consideration I have absolute confidence that we will see similar price action to when it hit £8/9 given that FARN now offers so much more than just T. But it’s very important to first consider the downside when positioning for what will be one hell of a rollacoaster.

With many articles released that supports the combination therapies including IFN-B and that we were not pulled from the WHO trials when others were, I can’t help but have a confirmation bias, that could be good or bad.

I have seen a number of reposts to suggest that IFN-B is now being tested in conjunction with Remdisiver, this is a massive positive for Traumakine imo.

https://twitter.com/santiagoangelp/status/1287820919218593792?s=21

First of many updates to come in this news rich period

Interesting chart here too,

https://twitter.com/antmwah/status/1287440857969426434?s=21

https://www.pharmaceutical-journal.com/research/review-article/investigational-treatments-for-covid-19/20208051.article

The ‘Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia’ has 198 active sites with 1008 total patients randomised to date over 14 countries, including the UK[87]. It now includes a new domain-specific for immune-modulating treatment, including interferon-ß-1a, as part of the COVID-19 response. This has been included as many patients with COVID-19 infection present with community-acquired pneumonia. The drug will be administered intravenously through either a central or peripheral line once each day for six days or up to hospital discharge — whichever is shorter[87].

Q - This is exactly how I am assessing the situation in terms of valuation before any results from solidarity or Remap results are released.

We can expect further results on Clevergen in the interim and a possible partnership. We also have the fact that T has already been through one set of phase three trials and the proposition has now been somewhat derisked.

My first target before even considering derisking my position is £8/9. We have an a lot to look forward to.